Can we do a better job preventing clinically-relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy?
Minor modifications in the standard "dose reduction" strategy commonly employed in the presence of developing carboplatin/paclitaxel-induced peripheral neuropathy may favorably impact the quality-of-life associated with use of this important combination chemotherapy regimen.
Markman
Maurie
M
The Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. markman@ccf.org
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects*; D018450:Disease Progression; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control* / Q000523:psychology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic
D016190:Carboplatin; D017239:Paclitaxel